CERS - Cerus Corp.: Record Revenue Warrants A Slight Change In Strategy
- Cerus Corporation once again reports record growth, however, the market has throttled any momentum in the share price. Despite the lackluster price action, I remain bullish on CERS.
- The FDA compliance date in October is quickly approaching. It is possible we see a significant inflection point in INTERCEPT sales in the coming quarters.
- My CERS trading strategy has generated profits, however, I am looking to make a slight alteration in anticipation of a potential breakout in the coming quarters.
For further details see:
Cerus Corp.: Record Revenue Warrants A Slight Change In Strategy